ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.
Jan 23, 2017
Novartis’ Continuous Dividend Growth and Promising Pipeline
Image Shown: Novartis’ dividend history, source: Novartis. Novartis may be in the penalty box, but a healthy dividend growth track record and a promising pipeline may be difficult to overlook. Let’s dig in.
Jan 21, 2017
Calendar Fourth Quarter Earnings Roundup: IBM, GE, PG, UNP
Image Source: texasfeelLet's get our thoughts on calendar fourth-quarter performance from a few giants in their respective industries.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.
Jan 19, 2017
Fair Value Estimate Changes: Facebook, Twitter, Caterpillar and More...
Let's have a look at the reasons behind several of the recent fair value changes we've made on companies across our coverage universe as of late.
Jan 19, 2017
Netflix: Is NOW Finally the Time?
Netflix’s shares are soaring, and we are licking our proverbial chops on the opportunity to add puts to the Best Ideas Newsletter portfolio. The bubble in Netflix’s shares continues to inflate—and that spells opportunity for bears, but at the right price at the right time. For now, we’re going to continue to watch shares run higher until we’re finally ready to take a stab at them. It’s been about a year since we highlighted our concerns about Netflix’s valuation, but our patience has paid off as we watched shares move ever-higher -- timing is pretty much everything when it comes to betting on the decline of a stock price via put options, and we’re being careful. Options aren’t for everybody.
Jan 18, 2017
Kinder Morgan Continues to Chop Down Its Debt Load
Image Source: Loren Kerns. Kinder Morgan continues to hover around our ~$20 fair value estimate for shares as the pipeline giant works to get its financial house in order.
Jan 15, 2017
The Coming “Goldman Sachs Era”
Image Source: Jussi. Valuentum covers recent developments in the financials sector, including hopes for a relaxation of certain prohibitive Dodd-Frank rules that, if repealed, could pave the way for improved economic returns across the banking sector during the Trump administration. A look back at the month of September 2008, and how Goldman Sachs may very well shape the financial markets during the next few years are two other areas in the piece. Financials stocks have come roaring back since Trump was elected the 45th President of the United States. We've participated.
Jan 13, 2017
Cardinal Health: An Undervalued Free Cash Flow Generating Powerhouse
Image Source: Lisa Brewster. Cardinal Health reset investor expectations lower when it cut its fiscal 2017 guidance late October. The company operates in an attractive oligopolistic industry and is trading at less than 14 times current fiscal-year earnings with a free cash flow yield north of 10%. Is it worth a look?
Jan 11, 2017
Pedal to the Metal for GM Heading Into 2017
Image Source: Abdullah AlBargan. Shares of GM are leaping again, this time on a 2017 guidance update.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.